HERON Obtained Medical Material License in Taiwan and Launched the First Domestic Targeted Cancer Radiation Therapy Device

HERON today officially obtained the medical device license for AB-BNCT equipment, which marks an important milestone in the field of cancer treatment in Taiwan. In the future, we will work closely with major medical centers to develop the clinical application of BNCT and bring new tools for cancer treatment to patients. Since the technology transfer from Tsinghua University and Industrial Technology Research Institute (ITRI) in 2017, HERON has focused on the development of AB-BNCT technology. The successful symbolizes Taiwan's ability to develop cancer treatment systems in-house, instead of relying on foreign vendors. The technological breakthrough not only proves the excellent technical ability of Taiwan, but also the neutron efficiency of its patented technology is the top in the world. Compared with similar systems from international manufacturers, it has lower activation and effectively reduces radiation exposure. The strong technical capabilities of Horon Technology is ready to be based in Taiwan and step into the world.
 This year, HERON will initiate clinical trials with CDMOs in Taiwan to develop a boron-containing drug (BPA), to target recurrent head and neck cancers, and will collaborate with medical centers in the north, central, and south of Taiwan to conduct clinical trials. We hope the trial will be completed and the drug certificate will be obtained in 2026. At the same time, research-based trials will also be conducted, including meningioma, brain cancer, breast cancer and lung cancer. The Clinical Medicine Center has already begun planning for the expansion of the indications in the future.
 Cancer has been the top cause of death in Taiwan. Accurate diagnosis and personalized treatment are the top medical issues. In tandem with the government's policy of developing the precision medicine, HERON Technology has developed a screening technology (F18-BPA), which is coupled with molecular medical imaging technology, to make the diagnosis more accurate. This technology (F18-BPA) not only provides an indicator to predict the efficacy of treatment, but also provides a scientific basis for commercial insurance and NHI benefits in the future.
 BNCT technology has already gained a foothold in Taiwan's cancer treatment, and the combination of policy, clinical and technology support has made Taiwan a global leader in BNCT. In terms of policy, HERON has communicating with the government to gain support and recognition. On the clinical, the cooperation between HERON and China Medical University has entered a new chapter with the completion of the treatment base. In terms of technical, we have significant progress in developing more convenient positioning tools and system miniaturization.
 We will continue to improve AB-BNCT technology to bring revolutionary breakthroughs to cancer treatment in Taiwan, benefit more cancer patients and go international which is the strategic goal of HERON.

HERON Technology Obtains Taiwan's First Medical Device License for AB-BNCT Equipment.